We are the only pharmaceutical company solely focused on combating, preventing, and ultimately eradicating HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
We partner in research, in access and with the community because we believe that we are stronger together when it comes to working towards the UN target of ending the AIDS epidemic by 2030.
Of the 38 million people living with HIV globally, almost 75% live in low- and middle- income countries, and 27% are not on treatment.
We are committed to enabling access to our medicines to benefit people affected by HIV, regardless of their income, location, status, age or gender.
We support a growing community of researchers, policy makers, community organisations, advocates and other stakeholders who are interested in studying current HIV care practices.
Our aim is to challenge the status quo, and shape health policy and practices that can lead to an HIV-free future.
OUR STORIES: SCIENCE AND INNOVATION
With significant progress made in the fight against HIV, how do we make sure that clinically proven tools are implemented into real-world settings?